Short answer
Fulgent Genetics, Inc. (FLGT) filed an 8-K current report with the SEC on June 2, 2026 reporting Item 8.01 (Other Events). Fulgent presenting updated FID-007 plus cetuximab data in recurrent/metastatic HNSCC at ASCO 2026.
Fulgent Genetics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Fulgent presenting updated FID-007 plus cetuximab data in recurrent/metastatic HNSCC at ASCO 2026
- Rapid Oral Abstract Session elevates visibility for FID-007’s oncology development program
- Abstract #6020 follows the full abstract released May 21, 2026
- Investor focus: updated clinical results and implications for FID-007’s advancement in HNSCC
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Fulgent Genetics, Inc. 8-K filings
Get the next FLGT 8-K as it lands
Follow FLGT for push alerts, or ask the research agent what this filing means.